Specific metabolic biomarkers as risk and prognostic factors in colorectal cancer

World Journal of Gastroenterology

Volumn , Issue 29, 2014, Pages 9759-9774

  Muc Wierzgoń, Małgorzata ^a   Nowakowska Zajdel, Ewa ^a   Dzie¸gielewska Ge¸siak, Sylwia ^a   Kokot, Teresa ^a   Klakla, Katarzyna ^a   Fatyga, Edyta ^a   Grochowska Niedworok, Elzbieta ^a   Waniczek, Dariusz ^a   Wierzgoń, Janusz ^b  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Adipokines; Colorectal cancer; Dyslipidemias; Insulin like growth factor system; Metabolic biomarkers; Prognosis; Risk

Indexed keywords

ADIPOCYTOKINE RECEPTOR; ADIPONECTIN RECEPTOR; BIOLOGICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LEPTIN RECEPTOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; RESISTIN; SOMATOMEDIN; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C RECEPTOR; ADIPOCYTOKINE; ADIPONECTIN; LEPTIN; SOMATOMEDIN BINDING PROTEIN; TUMOR MARKER; LIPID;

CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; COLON CARCINOGENESIS; COLORECTAL CANCER; DYSLIPIDEMIA; GENE MUTATION; GENE OVEREXPRESSION; GLUCOSE HOMEOSTASIS; HUMAN; HYPERINSULINEMIA; NONHUMAN; OBESITY; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; LIPOGENESIS; METABOLIC DISORDER; PREDICTION; PROGNOSTIC ASSESSMENT; RISK ASSESSMENT; SMOOTH MUSCLE FIBER; ANIMAL; BLOOD; COLORECTAL NEOPLASMS; COMPLICATION; DISORDERS OF CARBOHYDRATE METABOLISM; METABOLISM; METABOLOMICS; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; RISK FACTOR;

ADIPOKINES; ANIMALS; COLORECTAL NEOPLASMS; DYSLIPIDEMIAS; GLUCOSE METABOLISM DISORDERS; HUMANS; LIPIDS; METABOLOMICS; OBESITY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SOMATOMEDINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905842773     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i29.9759     Document Type: Review

References (183)

1. Vasan RS. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-2362 [PMID: 16702488 DOI: 10.1161/CIRCULATIONAHA.104.482570]
2. Montgomery JE, Brown JR. Metabolic biomarkers for predicting cardiovascular disease. Vasc Health Risk Manag 2013; 9: 37-45 [PMID: 23386789 DOI: 10.2147/VHRM.S30378]
3. Hojs R, Bevc S, Ekart R. Biomarkers in hemodialysis patients. Adv Clin Chem 2012; 57: 29-56 [PMID: 22870586 DOI: 10.1016/B978-0-12-394384-2.00002-4]
4. Biomarkers Definitions Working Group . Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95 [PMID: 11240971 DOI: 10.1067/mcp.2001.113989]
5. Brünner N. What Is the Difference Between "Predictive and Prognostic Biomarkers"? Can you Give Some Examples? Connection 2009: 13: 18-19
6. Research Advocacy Network. Biomarkers in Cancer: An Introductory Guide for Advocates. USA: Research Advocacy Network, 2010: 1-81
7. Kumar M, Sarin SK. Biomarkers of diseases in medicine. Curr Trends Sci 2009; 70: 403-417
8. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx 2004; 1: 182-188 [PMID: 15717018 DOI: 10.1602/neurorx.1.2.182]
9. Baumgartner C, Osl M, Netzer M, Baumgartner D. Bioinformatic-driven search for metabolic biomarkers in disease. J Clin Bioinforma 2011; 1: 2 [PMID: 21884622 DOI: 10.1186/2043-9113-1-2]
10. NCI Dictionary of Cancer Terms . Biomarker. Available from: URL: http://www.cancer.gov/dictionary?cdrid=45618
11. Tanaka T, Tanaka M, Tanaka T, Ishigamori R. Biomarkers for colorectal cancer. Int J Mol Sci 2010; 11: 3209-3225 [PMID: 20957089 DOI: 10.3390/ijms11093209]
12. Sarker D, Workman P. Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 2007; 96: 213-268 [PMID: 17161682 DOI: 10.1016/S0065-230X(06)96008-4]
13. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30 [PMID: 23335087 DOI: 10.3322/caac.21166]
14. Purim O, Gordon N, Brenner B. Cancer of the colon and rectum: potential effects of sex-age interactions on incidence and outcome. Med Sci Monit 2013; 19: 203-209 [PMID: 23511310 DOI: 10.12659/MSM.883842]
15. Debarros M, Steele SR. Colorectal cancer screening in an equal access healthcare system. J Cancer 2013; 4: 270-280 [PMID: 23459768]
16. Nowakowska-Zajdel E, Wierzchowiec O, Kokot T, Fatyga E, Muc-Wierzgon M. Metabolic Abnormalities in Colorectal Cancer Patients. J Endocrinol Metab 2012; 2: 135-138
17. Burn J, Mathers J, Bishop DT. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent Results Cancer Res 2013; 191: 157-183 [PMID: 22893205 DOI: 10.1007/978-3-642-30331-9-9]
18. Doubeni CA, Laiyemo AO, Major JM, Schootman M, Lian M, Park Y, Graubard BI, Hollenbeck AR, Sinha R. Socioeconomic status and the risk of colorectal cancer: an analysis of more than a half million adults in the National Institutes of Health-AARP Diet and Health Study. Cancer 2012; 118: 3636-3644 [PMID: 22898918 DOI: 10.1002/cncr.26677]
19. Zhang X, Smith-Warner SA, Chan AT, Wu K, Spiegelman D, Fuchs CS, Willett WC, Giovannucci EL. Aspirin use, body mass index, physical activity, plasma C-peptide, and colon cancer risk in US health professionals. Am J Epidemiol 2011; 174: 459-467 [PMID: 21673123 DOI: 10.1093/aje/kwr115]
20. Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg 2009; 22: 191-197 [PMID: 21037809 DOI: 10.1055/s-0029-1242458]
21. Riboli E. The European Prospective Investigation into Cancer and Nutrition (EPIC): plans and progress. J Nutr 2001; 131: 170S-175S [PMID: 11208958]
22. Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? Am J Pathol 2006; 169: 1505-1522 [PMID: 17071576 DOI: 10.2353/ajpath.2006.051090]
23. Stepien M, Rosniak-Bak K, Paradowski M, Misztal M, Kujawski K, Banach M, Rysz J. Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results. Med Sci Monit 2011; 17: PR13-PR18 [PMID: 22037753 DOI: 10.12659/MSM.882030]
24. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr 2007; 86: s836-s842 [PMID: 18265477]
25. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Rafaniello C, Panagiotakos DB, Giugliano D. Colorectal cancer association with metabolic syndrome and its components: a systematic review with meta-analysis. Endocrine 2013; 44: 634-647 [PMID: 23546613]
26. Stocks T, Lukanova A, Bjørge T, Ulmer H, Manjer J, Almquist M, Concin H, Engeland A, Hallmans G, Nagel G, Tretli S, Veierød MB, Jonsson H, Stattin P. Metabolic factors and the risk of colorectal cancer in 580,000 men and women in the metabolic syndrome and cancer project (Me-Can). Cancer 2011; 117: 2398-2407 [PMID: 24048787 DOI: 10.1002/cncr.25772]
27. Aleksandrova K, Nimptsch K, Pischon T. Influence of Obesity and Related Metabolic Alterations on Colorectal Cancer Risk. Curr Nutr Rep 2013; 2: 1-9 [PMID: 23396857 DOI: 10.1007/s13668-012-0036-9]
28. Szymocha M, Bryła M, Manicka-Bryła M. The Obesity Epidemic in 21st Century. Post Hig Med Dosw 2009; 119: 2007-2012
29. Aleksandrova K, Drogan D, Boeing H, Jenab M, Bas Bueno-de- Mesquita H, Jansen E, van Duijnhoven FJ, Rinaldi S, Fedirko V, Romieu I, Kaaks R, Riboli E, Gunter MJ, Romaguera D, Westhpal S, Overvad K, Tjønneland A, Halkjaer J, Boutron-Ruault MC, Clavel-Chapelon F, Lukanova A, Trichopoulou A, Trichopoulos D, Vidalis P, Panico S, Agnoli C, Palli D, Tumino R, Vineis P, Buckland G, Sánchez-Cruz JJ, Dorronsoro M, Díaz MJ, Barricarte A, Ramon Quiros J, Peeters PH, May AM, Hallmans G, Palmqvist R, Crowe FL, Khaw KT, Wareham N, Pischon T. Adiposity, mediating biomarkers and risk of colon cancer in the European prospective investigation into cancer and nutrition study. Int J Cancer 2014; 134: 612-621 [PMID: 23824948 DOI: 10.1002/ijc.28368]
30. Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin H. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One 2013; 8: e53916 [PMID: 23349764]
31. Prieto-Hontoria PL, Pérez-Matute P, Fernández-Galilea M, Bustos M, Martínez JA, Moreno-Aliaga MJ. Role of obesity-associated dysfunctional adipose tissue in cancer: a molecular nutrition approach. Biochim Biophys Acta 2011; 1807: 664-678 [PMID: 21111705 DOI: 10.1016/j.bbabio.2010.11.004]
32. Hursting SD, Dunlap SM. Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. Ann N Y Acad Sci 2012; 1271: 82-87 [PMID: 23050968 DOI: 10.1111/j.1749-6632.2012.06737.x]
33. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr 2006; 83: 461S-465S [PMID: 16470013]
34. Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2011; 7: 11-24 [PMID: 20956999]
35. Naukkarinen J . Molecular Background of Common Dyslipidemias. Helsinki: National Public Health Institute, 2008: 43-54
36. van Duijnhoven FJ, Bueno-De-Mesquita HB, Calligaro M, Jenab M, Pischon T, Jansen EH, Frohlich J, Ayyobi A, Overvad K, Toft-Petersen AP, Tjønneland A, Hansen L, Boutron- Ruault MC, Clavel-Chapelon F, Cottet V, Palli D, Tagliabue G, Panico S, Tumino R, Vineis P, Kaaks R, Teucher B, Boeing H, Drogan D, Trichopoulou A, Lagiou P, Dilis V, Peeters PH, Siersema PD, Rodríguez L, González CA, Molina-Montes E, Dorronsoro M, Tormo MJ, Barricarte A, Palmqvist R, Hallmans G, Khaw KT, Tsilidis KK, Crowe FL, Chajes V, Fedirko V, Rinaldi S, Norat T, Riboli E. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 2011; 60: 1094-1102 [PMID: 21383385]
37. Gallagher EJ, LeRoith D. Epidemiology and molecular mechanisms tying obesity, diabetes, and the metabolic syndrome with cancer. Diabetes Care 2013; 36 Suppl 2: S233-S239 [PMID: 23882051 DOI: 10.2337/dcS13-2001]
38. Melvin JC, Holmberg L, Rohrmann S, Loda M, Van Hemelrijck M. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol 2013; 2013: 823849 [PMID: 23401687]
39. Yamada K, Araki S, Tamura M, Sakai I, Takahashi Y, Kashihara H, Kono S. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol 1998; 27: 794-798 [PMID: 9839735 DOI: 10.1093/ije/27.5.794]
40. Wulaningsih W, Garmo H, Holmberg L, Hammar N, Jungner I, Walldius G, Van Hemelrijck M. Serum Lipids and the Risk of Gastrointestinal Malignancies in the Swedish AMORIS Study. J Cancer Epidemiol 2012; 2012: 792034 [PMID: 22969802 DOI: 10.1155/2012/792034]
41. Strohmaier S, Edlinger M, Manjer J, Stocks T, Bjørge T, Borena W, Häggström C, Engeland A, Nagel G, Almquist M, Selmer R, Tretli S, Concin H, Hallmans G, Jonsson H, Stattin P, Ulmer H. Total serum cholesterol and cancer incidence in the Metabolic syndrome and Cancer Project (Me-Can). PLoS One 2013; 8: e54242 [PMID: 23372693]
42. Schatzkin A, Hoover RN, Taylor PR, Ziegler RG, Carter CL, Albanes D, Larson DB, Licitra LM. Site-specific analysis of total serum cholesterol and incident cancer in the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Cancer Res 1988; 48: 452-458 [PMID: 3335013]
43. Kitahara CM, Berrington de González A, Freedman ND, Huxley R, Mok Y, Jee SH, Samet JM. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol 2011; 29: 1592-1598 [PMID: 21422422 DOI: 10.1200/JCO.2010.31.5200]
44. Chung YW, Han DS, Park YK, Son BK, Paik CH, Lee HL, Jeon YC, Sohn JH. Association of obesity, serum glucose and lipids with the risk of advanced colorectal adenoma and cancer: a case-control study in Korea. Dig Liver Dis 2006; 38: 668-672 [PMID: 16790371 DOI: 10.1016/j.dld.2006.05.014]
45. Notarnicola M, Altomare DF, Correale M, Ruggieri E, D' Attoma B, Mastrosimini A, Guerra V, Caruso MG. Serum lipid profile in colorectal cancer patients with and without synchronous distant metastases. Oncology 2005; 68: 371-374 [PMID: 16020965 DOI: 10.1159/000086977]
46. Ulmer H, Borena W, Rapp K, Klenk J, Strasak A, Diem G, Concin H, Nagel G. Serum triglyceride concentrations and cancer risk in a large cohort study in Austria. Br J Cancer 2009; 101: 1202-1206 [PMID: 19690552 DOI: 10.1038/sj.bjc.6605264]
47. Aleksandrova K, Boeing H, Jenab M, Bas Bueno-de-Mesquita H, Jansen E, van Duijnhoven FJ, Fedirko V, Rinaldi S, Romieu I, Riboli E, Romaguera D, Overvad K, Østergaard JN, Olsen A, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Masala G, Agnoli C, Panico S, Tumino R, Vineis P, Kaaks R, Lukanova A, Trichopoulou A, Naska A, Bamia C, Peeters PH, Rodríguez L, Buckland G, Sánchez MJ, Dorronsoro M, Huerta JM, Barricarte A, Hallmans G, Palmqvist R, Khaw KT, Wareham N, Allen NE, Tsilidis KK, Pischon T. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res (Phila) 2011; 4: 1873-1883 [PMID: 21697276 DOI: 10.1158/1940-6207.CAPR-11-0218]
48. Su F, Grijalva V, Navab K, Ganapathy E, Meriwether D, Imaizumi S, Navab M, Fogelman AM, Reddy ST, Farias-Eisner R. HDL mimetics inhibit tumor development in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther 2012; 11: 1311-1319 [PMID: 22416044 DOI: 10.1158/1535-7163.MCT-11-0905]
49. Ahn J, Lim U, Weinstein SJ, Schatzkin A, Hayes RB, Virtamo J, Albanes D. Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer. Cancer Epidemiol Biomarkers Prev 2009; 18: 2814-2821 [PMID: 19887581 DOI: 10.1158/1055-9965.EPI-08-1248]
50. Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin North Am 2008; 37: 753-768, x-xi [PMID: 18775362 DOI: 10.1016/j.ecl.2008.07.002]
51. Trujillo ME, Scherer PE. Adipose tissue-derived factors: impact on health and disease. Endocr Rev 2006; 27: 762-778 [PMID: 17056740 DOI: 10.1210/er.2006-0033]
52. Zhang F, Chen Y, Heiman M, Dimarchi R. Leptin: structure, function and biology. Vitam Horm 2005; 71: 345-372 [PMID: 16112274 DOI: 10.1016/S0083-6729(05)71012-8]
53. Iikuni N, Lam QL, Lu L, Matarese G, La Cava A. Leptin and Inflammation. Curr Immunol Rev 2008; 4: 70-79 [PMID: 20198122 DOI: 10.2174/157339508784325046]
54. Dutta D, Ghosh S, Pandit K, Mukhopadhyay P, Chowdhury S. Leptin and cancer: Pathogenesis and modulation. Indian J Endocrinol Metab 2012; 16: S596-S600 [PMID: 23565495 DOI: 10.4103/2230-8210.105577]
55. Stachowicz M, Mazurek U, Nowakowska-Zajdel E, Muc-Wierzgoń M. Leptin, obesity and colorectal cancer. Pol J Environ Stud 2010; 19: 225-229
56. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res 2004; 10: 4325-4331 [PMID: 15240518 DOI: 10.1158/1078-0432.CCR-03-0749]
57. Jaffe T, Schwartz B. Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways. Int J Cancer 2008; 123: 2543-2556 [PMID: 18767036 DOI: 10.1002/ijc.23821]
58. Burguera B, Brunetto A, Garcia-Ocana A, Teijeiro R, Esplen J, Thomas T, Couce ME, Zhao A. Leptin increases proliferation of human steosarcoma cells through activation of PI(3)-K and MAPK pathways. Med Sci Monit 2006; 12: BR341-BR349 [PMID: 17072262]
59. Amemori S, Ootani A, Aoki S, Fujise T, Shimoda R, Kakimoto T, Shiraishi R, Sakata Y, Tsunada S, Iwakiri R, Fujimoto K. Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro. Am J Physiol Gastrointest Liver Physiol 2007; 292: G923-G929 [PMID: 17170030 DOI: 10.1152/ajpgi.00145.2006]
60. Ratke J, Entschladen F, Niggemann B, Zänker KS, Lang K. Leptin stimulates the migration of colon carcinoma cells by multiple signaling pathways. Endocr Relat Cancer 2010; 17: 179-189 [PMID: 19952122 DOI: 10.1677/ERC-09-0225]
61. Wang D, Chen J, Chen H, Duan Z, Xu Q, Wei M, Wang L, Zhong M. Leptin regulates proliferation and apoptosis of colorectal carcinoma through PI3K/Akt/mTOR signalling pathway. J Biosci 2012; 37: 91-101 [PMID: 22357207 DOI: 10.1007/s12038-011-9172-4]
62. Sikalidis AK, Varamini B. Roles of hormones and signaling molecules in describing the relationship between obesity and colon cancer. Pathol Oncol Res 2011; 17: 785-790 [PMID: 21221874 DOI: 10.1007/s12253-010-9352-9]
63. Slattery ML, Wolff RK, Herrick J, Caan BJ, Potter JD. Leptin and leptin receptor genotypes and colon cancer: genegene and gene-lifestyle interactions. Int J Cancer 2008; 122: 1611-1617 [PMID: 18059035 DOI: 10.1002/ijc.23135]
64. Ogino S, Shima K, Baba Y, Nosho K, Irahara N, Kure S, Chen L, Toyoda S, Kirkner GJ, Wang YL, Giovannucci EL, Fuchs CS. Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPAR-gamma) is associated with good prognosis. Gastroenterology 2009; 136: 1242-1250 [PMID: 19186181 DOI: 10.1053/j.gastro.2008.12.048]
65. Bartucci M, Svensson S, Ricci-Vitiani L, Dattilo R, Biffoni M, Signore M, Ferla R, De Maria R, Surmacz E. Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. Endocr Relat Cancer 2010; 17: 823-833 [PMID: 20603394 DOI: 10.1677/ERC-10-0083]
66. Hoda MR, Keely SJ, Bertelsen LS, Junger WG, Dharmasena D, Barrett KE. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br J Surg 2007; 94: 346-354 [PMID: 17212381 DOI: 10.1002/bjs.5530]
67. Chia VM, Newcomb PA, Lampe JW, White E, Mandelson MT, McTiernan A, Potter JD. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2007; 16: 2697-2703 [PMID: 18086776 DOI: 10.1158/1055-9965.EPI-07-0467]
68. Tamakoshi K, Toyoshima H, Wakai K, Kojima M, Suzuki K, Watanabe Y, Hayakawa N, Yatsuya H, Kondo T, Tokudome S, Hashimoto S, Suzuki S, Kawado M, Ozasa K, Ito Y, Tamakoshi A. Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. Oncology 2005; 68: 454-461 [PMID: 16020976 DOI: 10.1159/000086988]
69. Guadagni F, Roselli M, Martini F, Spila A, Riondino S, D' Alessandro R, Del Monte G, Formica V, Laudisi A, Portarena I, Palmirotta R, Ferroni P. Prognostic significance of serum adipokine levels in colorectal cancer patients. Anticancer Res 2009; 29: 3321-3327 [PMID: 19661351]
70. Aleksandrova K, Boeing H, Jenab M, Bueno-de-Mesquita HB, Jansen E, van Duijnhoven FJ, Rinaldi S, Fedirko V, Romieu I, Riboli E, Gunter MJ, Westphal S, Overvad K, Tjønneland A, Halkjær J, Racine A, Boutron-Ruault MC, Clavel- Chapelon F, Kaaks R, Lukanova A, Trichopoulou A, Lagiou P, Trichopoulos D, Mattiello A, Pala V, Palli D, Tumino R, Vineis P, Buckland G, Sánchez MJ, Amiano P, Huerta JM, Barricarte A, Menéndez V, Peeters PH, Söderberg S, Palmqvist R, Allen NE, Crowe FL, Khaw KT, Wareham N, Pischon T. Leptin and soluble leptin receptor in risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition cohort. Cancer Res 2012; 72: 5328-5337 [PMID: 22926557 DOI: 10.1158/0008-5472.CAN-12-0465]
71. Cong JC, Dai XW, Shen MY, Wang JJ, Chen CS, Zhang H, Qiao L. Expression of obesity hormone leptin in human colorectal cancer. Chin J Cancer Res 2009; 21: 142-146 [DOI: 10.1007/s11670-009-0142-4]
72. Stachowicz M, Mazurek U, Nowakowska-Zajdel E, Niedworok E, Fatyga E, Muc-Wierzgon M. Leptin and its receptors in obese patients with colorectal cancer. J Biol Regul Homeost Agents 2010; 24: 287-295 [PMID: 20846476]
73. Arpaci F, Yilmaz MI, Ozet A, Ayta H, Ozturk B, Komurcu S, Ozata M. Low serum leptin level in colon cancer patients without significant weight loss. Tumori 2002; 88: 147-149 [PMID: 12088256]
74. Dalamaga M, Diakopoulos KN, Mantzoros CS. The role of adiponectin in cancer: a review of current evidence. Endocr Rev 2012; 33: 547-594 [PMID: 22547160 DOI: 10.1210/er.2011-1015]
75. Housa D, Housová J, Vernerová Z, Haluzík M. Adipocytokines and cancer. Physiol Res 2006; 55: 233-244 [PMID: 16238454]
76. Guzel S, Yalcin A. Adiponectin and Its Protective Effects. J Biol Environ Sci 2012; 6: 135-139
77. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006; 55: 249-259 [PMID: 16380500 DOI: 10.2337/diabetes.55.01.06.db05-1105]
78. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K, Kozono H, Hada Y, Ogata H, Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 13: 332-339 [PMID: 17268472 DOI: 10.1038/nm1557]
79. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: regulation of its production and its role in human diseases. Hormones (Athens) 2012; 11: 8-20 [PMID: 22450341]
80. Williams AS, Kasahara DI, Verbout NG, Fedulov AV, Zhu M, Si H, Wurmbrand AP, Hug C, Ranscht B, Shore SA. Role of the adiponectin binding protein, T-cadherin (Cdh13), in allergic airways responses in mice. PLoS One 2012; 7: e41088 [PMID: 22815927 DOI: 10.1371/journal.pone.0041088]
81. Gornick MC, Rennert G, Moreno V, Gruber SB. Adiponectin gene and risk of colorectal cancer. Br J Cancer 2011; 105: 562-564 [PMID: 21829206 DOI: 10.1038/bjc.2011.259]
82. Takahashi H, Takayama T, Yoneda K, Endo H, Iida H, Sugiyama M, Fujita K, Yoneda M, Inamori M, Abe Y, Saito S, Wada K, Nakagama H, Nakajima A. Association of visceral fat accumulation and plasma adiponectin with rectal dysplastic aberrant crypt foci in a clinical population. Cancer Sci 2009; 100: 29-32 [PMID: 19018760 DOI: 10.1111/j.1349-7006.2008.00994.x]
83. Sugiyama M, Takahashi H, Hosono K, Endo H, Kato S, Yoneda K, Nozaki Y, Fujita K, Yoneda M, Wada K, Nakagama H, Nakajima A. Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 2009; 34: 339-344 [PMID: 19148467]
84. Obeid S, Hebbard L. Role of adiponectin and its receptors in cancer. Cancer Biol Med 2012; 9: 213-220 [PMID: 23691481]
85. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, Kato K, Hamaguchi T, Shimada Y. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 2010; 101: 1286-1291 [PMID: 20331631 DOI: 10.1111/j.1349-7006.2010.01518.x]
86. Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH, Xiao SD. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. J Dig Dis 2011; 12: 234-244 [PMID: 21791018 DOI: 10.1111/j.1751-2980.2011.00504.x]
87. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst 2005; 97: 1688-1694 [PMID: 16288122 DOI: 10.1093/jnci/dji376]
88. Fukumoto J, Otake T, Tajima O, Tabata S, Abe H, Mizoue T, Ohnaka K, Kono S. Adiponectin and colorectal adenomas: Self Defense Forces Health Study. Cancer Sci 2008; 99: 781-786 [PMID: 18377427 DOI: 10.1111/j.1349-7006.2008.00745.x]
89. Aleksandrova K, Boeing H, Jenab M, Bueno-de-Mesquita HB, Jansen E, van Duijnhoven FJ, Fedirko V, Rinaldi S, Romieu I, Riboli E, Romaguera D, Westphal S, Overvad K, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Kaaks R, Lukanova A, Trichopoulou A, Lagiou P, Trichopoulos D, Agnoli C, Mattiello A, Saieva C, Vineis P, Tumino R, Peeters PH, Argüelles M, Bonet C, Sánchez MJ, Dorronsoro M, Huerta JM, Barricarte A, Palmqvist R, Hallmans G, Khaw KT, Wareham N, Allen NE, Crowe FL, Pischon T. Total and high-molecular weight adiponectin and risk of colorectal cancer: the European Prospective Investigation into Cancer and Nutrition Study. Carcinogenesis 2012; 33: 1211-1218 [PMID: 22431719 DOI: 10.1093/carcin/bgs133]
90. Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, Baron JA, Ahsan H, Mantzoros C, Pasche B. Variants of the adiponectin (ADIPOQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA 2008; 300: 1523-1531 [PMID: 18827209 DOI: 10.1001/jama.300.13.1523]
91. Otake S, Takeda H, Fujishima S, Fukui T, Orii T, Sato T, Sasaki Y, Nishise S, Kawata S. Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol 2010; 16: 1252-1257 [PMID: 20222170 DOI: 10.3748/wjg.v16.i10.1252]
92. Gialamas SP, Petridou ET, Tseleni-Balafouta S, Spyridopoulos TN, Matsoukis IL, Kondi-Pafiti A, Zografos G, Mantzoros CS. Serum adiponectin levels and tissue expression of adiponectin receptors are associated with risk, stage, and grade of colorectal cancer. Metabolism 2011; 60: 1530-1538 [PMID: 21632074 DOI: 10.1016/j.metabol.2011.03.020]
93. He B, Pan Y, Zhang Y, Bao Q, Chen L, Nie Z, Gu L, Xu Y, Wang S. Effects of genetic variations in the adiponectin pathway genes on the risk of colorectal cancer in the Chinese population. BMC Med Genet 2011; 12: 94 [PMID: 21749709 DOI: 10.1186/1471-2350-12-94]
94. Liu L, Zhong R, Wei S, Yin JY, Xiang H, Zou L, Chen W, Chen JG, Zheng XW, Huang LJ, Zhu BB, Chen Q, Duan SY, Rui R, Yang BF, Sun JW, Xie DS, Xu YH, Miao XP, Nie SF. Interactions between genetic variants in the adiponectin, adiponectin receptor 1 and environmental factors on the risk of colorectal cancer. PLoS One 2011; 6: e27301 [PMID: 22087284 DOI: 10.1371/journal.pone.0027301]
95. Song M, Zhang X, Wu K, Ogino S, Fuchs CS, Giovannucci EL, Chan AT. Plasma adiponectin and soluble leptin receptor and risk of colorectal cancer: a prospective study. Cancer Prev Res (Phila) 2013; 6: 875-885 [PMID: 23872505 DOI: 10.1158/1940-6207.CAPR-13-0169]
96. Ferroni P, Palmirotta R, Spila A, Martini F, Raparelli V, Fossile E, Mariotti S, Del Monte G, Buonomo O, Roselli M, Guadagni F. Prognostic significance of adiponectin levels in nonmetastatic colorectal cancer. Anticancer Res 2007; 27: 483-489 [PMID: 17348431]
97. Barnes KM, Miner JL. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Pept Sci 2009; 10: 96-107 [DOI: 10.2174/138920309787315239]
98. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, Macphee CH, Smith SA. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 2003; 300: 472-476 [PMID: 12504108 DOI: 10.1016/S0006-291X(02)02841-3]
99. Benomar Y, Gertler A, De Lacy P, Crépin D, Ould Hamouda H, Riffault L, Taouis M. Central resistin overexposure induces insulin resistance through Toll-like receptor 4. Diabetes 2013; 62: 102-114 [PMID: 22961082 DOI: 10.2337/db12-0237]
100. Daquinag AC, Zhang Y, Amaya-Manzanares F, Simmons PJ, Kolonin MG. An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell 2011; 9: 74-86 [PMID: 21683670 DOI: 10.1016/j.stem.2011.05.017]
101. Lee S, Lee HC, Kwon YW, Cho Y, Lee SE, Yang HM, Kim JK, Cho HJ, Oh BH, Park YB, Kim HS. Identification of a Human Resistin Receptor That Mediates Inflammatory Actions. Circulation 2012; 126: A 13041
102. Rajala MW, Qi Y, Patel HR, Takahashi N, Banerjee R, Pajvani UB, Sinha MK, Gingerich RL, Scherer PE, Ahima RS. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes 2004; 53: 1671-1679 [PMID: 15220189 DOI: 10.2337/diabetes.53.7.1671]
103. Danese E, Montagnana M, Minicozzi AM, Bonafini S, Ruzzenente O, Gelati M, De Manzoni G, Lippi G, Guidi GC. The role of resistin in colorectal cancer. Clin Chim Acta 2012; 413: 760-764 [PMID: 22296675 DOI: 10.1016/j.cca.2012.01.019]
104. Al-Harithy RN, Al-Ghafari AB. Resistin in human colon cancer. Increased expression independently of resistin promoter C-180G genotype. Saudi Med J 2010; 31: 495-500 [PMID: 20464037]
105. Kumor A, Daniel P, Pietruczuk M, Małecka-Panas E. Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Colorectal Dis 2009; 24: 275-281 [PMID: 18979105 DOI: 10.1007/s00384-008-0605-y]
106. Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430 [PMID: 15604363 DOI: 10.1126/science.1097243]
107. Adeghate E. Visfatin: structure, function and relation to diabetes mellitus and other dysfunctions. Curr Med Chem 2008; 15: 1851-1862 [PMID: 18691043 DOI: 10.2174/092986708785133004]
108. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, Tilg H. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758 [PMID: 17237424]
109. Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, Kato K, Hamaguchi T, Shimada Y. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009; 44: 685-690 [PMID: 19430715 DOI: 10.1007/s00535-009-0063-5]
110. Huang WS, Chen CN, Sze CI, Teng CC. Visfatin induces stromal cell-derived factor-1 expression by β1 integrin signaling in colorectal cancer cells. J Cell Physiol 2013; 228: 1017-1024 [PMID: 23042611 DOI: 10.1002/jcp.24248]
111. Chen M, Wang Y, Li Y, Zhao L, Ye S, Wang S, Yu C, Xie H. Association of plasma visfatin with risk of colorectal cancer: An observational study of Chinese patients. Asia Pac J Clin Oncol 2013; Epub ahead of print [PMID: 23910020]
112. Tulubas F, Mete R, Oznur M, Topcu B. The role of adipocytokines in colon cancer and adenomas. J Med Biochem 2013; 32: 135-142
113. LeRoith D, Baserga R, Helman L, Roberts CT. Insulin-like growth factors and cancer. Ann Intern Med 1995; 122: 54-59 [PMID: 7619109 DOI: 10.7326/0003-4819-122-1-199501010-00009]
114. Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 2000; 10: 297-305 [PMID: 11161960]
115. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-1489 [PMID: 10995803 DOI: 10.1093/jnci/92.18.1472]
116. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 2004; 363: 1346-1353 [PMID: 15110491 DOI: 10.1016/S0140-6736(04)16044-3]
117. Moschos SJ, Mantzoros CS. The role of the IGF system in cancer: from basic to clinical studies and clinical applications. Oncology 2002; 63: 317-332 [PMID: 12417786 DOI: 10.1159/000066230]
118. Alvino CL, Ong SC, McNeil KA, Delaine C, Booker GW, Wallace JC, Forbes BE. Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor activation by IGF-II. PLoS One 2011; 6: e27488 [PMID: 22140443 DOI: 10.1371/journal.pone.0027488]
119. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011; 1813: 1938-1945 [PMID: 21708191]
120. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 2005; 97: 1679-1687 [PMID: 16288121 DOI: 10.1093/jnci/dji375]
121. LeRoith D. Insulin-like growth factor I receptor signaling - overlapping or redundant pathways? Endocrinology 2000; 141: 1287-1288 [PMID: 10746630]
122. Giovannucci E, Michaud D. The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. Gastroenterology 2007; 132: 2208-2225 [PMID: 17498513 DOI: 10.1053/j.gastro.2007.03.050]
123. Ahmed RL, Schmitz KH, Anderson KE, Rosamond WD, Folsom AR. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006; 107: 28-36 [PMID: 16721800 DOI: 10.1002/cncr.21950]
124. Henderson KD, Goran MI, Kolonel LN, Henderson BE, Le Marchand L. Ethnic disparity in the relationship between obesity and plasma insulin-like growth factors: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 2006; 15: 2298-2302 [PMID: 17119061 DOI: 10.1158/1055-9965.EPI-06-0344]
125. Saydah S, Ballard-Barbash R, Potischman N. Association of metabolic syndrome with insulin-like growth factors among adults in the US. Cancer Causes Control 2009; 20: 1309-1316 [PMID: 19415508 DOI: 10.1007/s10552-009-9351-x]
126. Frezza EE, Wachtel MS, Chiriva-Internati M. Influence of obesity on the risk of developing colon cancer. Gut 2006; 55: 285-291 [PMID: 16239255 DOI: 10.1136/gut.2005.073163]
127. Nowakowska-Zajdel E, Muc-Wierzgoń M, Kokot T, Romanowski W, Zubelewicz-Szkodzińska B, Brodziak A, Wiczkowski A, Strzelczyk J, Kozowicz A. Serum insulin levels in patients with colorectal cancer. Pol Arch Med Wewn 2008; 118: 273-279 [PMID: 18619177]
128. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulinlike growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 2009; 27: 176-185 [PMID: 19064975 DOI: 10.1200/JCO.2008.17.9945]
129. Limburg PJ, Vierkant RA, Fredericksen ZS, Leibson CL, Rizza RA, Gupta AK, Ahlquist DA, Melton LJ, Sellers TA, Cerhan JR. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am J Gastroenterol 2006; 101: 1872-1879 [PMID: 16790032 DOI: 10.1111/j.1572-0241.2006.00725.x]
130. Oh SW, Kim YH, Choi YS, Chang DK, Son HJ, Rhee PL, Kim JJ, Rhee JC, Yun SH, Lee WY, Chun HK, Kim DH, Shim SG. The comparison of the risk factors and clinical manifestations of proximal and distal colorectal cancer. Dis Colon Rectum 2008; 51: 56-61 [PMID: 18030529 DOI: 10.1007/s10350-007-9083-5]
131. Yang YX, Hennessy S, Lewis JD. Type 2 diabetes mellitus and the risk of colorectal cancer. Clin Gastroenterol Hepatol 2005; 3: 587-594 [PMID: 15952101 DOI: 10.1016/S1542-3565(05)00152-7]
132. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012; 35: 2665-2673 [PMID: 23173135 DOI: 10.2337/dc12-0788]
133. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-1305 [PMID: 15849206 DOI: 10.1136/bmj.38415.708634.F7]
134. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, Bost F. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008; 27: 3576-3586 [PMID: 18212742 DOI: 10.1038/sj.onc.1211024]
135. Wang W, Guan KL. AMP-activated protein kinase and cancer. Acta Physiol (Oxf) 2009; 196: 55-63 [PMID: 19243571 DOI: 10.1111/j.1748-1716.2009.01980.x]
136. Glazer NL. Variation in the ATM gene may alter glycemic response to metformin. Circ Cardiovasc Genet 2011; 4: 210-211 [PMID: 21505202 DOI: 10.1161/CIRCGENETICS.111.960047]
137. Alexander A, Walker CL. Differential localization of ATM is correlated with activation of distinct downstream signaling pathways. Cell Cycle 2010; 9: 3685-3686 [PMID: 20890104 DOI: 10.4161/cc.9.18.13253]
138. Memmott RM, Dennis PA. LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol 2009; 27: e226; author reply e227 [PMID: 19858366 DOI: 10.1200/JCO.2009.25.3963]
139. Fontana L, Klein S, Holloszy JO. Long-term low-protein, low-calorie diet and endurance exercise modulate metabolic factors associated with cancer risk. Am J Clin Nutr 2006; 84: 1456-1462 [PMID: 17158430]
140. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928 [PMID: 19029956 DOI: 10.1038/nrc2536]
141. Ma J, Giovannucci E, Pollak M, Leavitt A, Tao Y, Gaziano JM, Stampfer MJ. A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst 2004; 96: 546-553 [PMID: 15069117 DOI: 10.1093/jnci/djh082]
142. Jenab M, Riboli E, Cleveland RJ, Norat T, Rinaldi S, Nieters A, Biessy C, Tjønneland A, Olsen A, Overvad K, Grønbaek H, Clavel-Chapelon F, Boutron-Ruault MC, Linseisen J, Boeing H, Pischon T, Trichopoulos D, Oikonomou E, Trichopoulou A, Panico S, Vineis P, Berrino F, Tumino R, Masala G, Peters PH, van Gils CH, Bueno-de-Mesquita HB, Ocké MC, Lund E, Mendez MA, Tormo MJ, Barricarte A, Martínez-García C, Dorronsoro M, Quirós JR, Hallmans G, Palmqvist R, Berglund G, Manjer J, Key T, Allen NE, Bingham S, Khaw KT, Cust A, Kaaks R. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2007; 121: 368-376 [PMID: 17372899 DOI: 10.1002/ijc.22697]
143. Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Howard BV, Wylie-Rosett J, Anderson GL, Ho GY, Kaplan RC, Li J, Xue X, Harris TG, Burk RD, Strickler HD. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res 2008; 68: 329-337 [PMID: 18172327 DOI: 10.1158/0008-5472.CAN-07-2946]
144. Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 2011; 30: 1174-1182 [PMID: 21102522 DOI: 10.1038/onc.2010.483]
145. Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB, Cryer B. Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig Dis Sci 2008; 53: 2486-2494 [PMID: 18409001 DOI: 10.1007/s10620-008-0264-4]
146. Miao Jonasson J, Cederholm J, Eliasson B, Zethelius B, Eeg- Olofsson K, Gudbjörnsdottir S. HbA1C and cancer risk in patients with type 2 diabetes--a nationwide populationbased prospective cohort study in Sweden. PLoS One 2012; 7: e38784 [PMID: 22719946 DOI: 10.1371/journal.pone.0038784]
147. Kaczka A, Kumor A, Pietruczuk M, Małecka-Panas E. [Serum concentration of insulin, C-peptide and insulin-like growth factor I in patients with colon adenomas and colorectal cancer]. Pol Merkur Lekarski 2007; 22: 373-375 [PMID: 17679371]
148. Nowakowska-Zajdel E. Insulinopodobne czynniki wzrostu u chorych na raka jelita grubego ze wsp?istniej?c? nadwag? i otyłos̈ci?: rozprawa habilitacyjna nr. Katowice 2008; ISBN 978-83-7509-090-1
149. Deng L, Gui Z, Zhao L, Wang J, Shen L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci 2012; 57: 1576-1585 [PMID: 22350783 DOI: 10.1007/s10620-012-2055-1]
150. Nowakowska-Zajdel E, Mazurek U, Ziółko E, Niedworok E, Fatyga E, Kokot T, Muc-Wierzgoń M. Analysis of expression profile of gene encoding proteins of signal cascades activated by insulin-like growth factors in colorectal cancer. Int J Immunopathol Pharmacol 2011; 24: 781-787 [PMID: 21978709]
151. Gao Y, Katki H, Graubard B, Pollak M, Martin M, Tao Y, Schoen RE, Church T, Hayes RB, Greene MH, Berndt SI. Serum IGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. Int J Cancer 2012; 131: E105-E113 [PMID: 21932422 DOI: 10.1002/ijc.26438]
152. Teramukai S, Rohan T, Lee KY, Eguchi H, Oda T, Kono S. Insulin-like growth factor (IGF)-I, IGF-binding protein-3 and colorectal adenomas in Japanese men. Jpn J Cancer Res 2002; 93: 1187-1194 [PMID: 12460458 DOI: 10.1111/j.1349-7006.2002.tb01222.x]
153. Keku TO, Lund PK, Galanko J, Simmons JG, Woosley JT, Sandler RS. Insulin resistance, apoptosis, and colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 2076-2081 [PMID: 16172212 DOI: 10.1158/1055-9965.EPI-05-0239]
154. Le Marchand L, Wang H, Rinaldi S, Kaaks R, Vogt TM, Yokochi L, Decker R. Associations of plasma C-peptide and IGFBP-1 levels with risk of colorectal adenoma in a multiethnic population. Cancer Epidemiol Biomarkers Prev 2010; 19: 1471-1477 [PMID: 20501760 DOI: 10.1158/1055-9965.EPI-10-0128]
155. Giovannucci E, Pollak MN, Platz EA, Willett WC, Stampfer MJ, Majeed N, Colditz GA, Speizer FE, Hankinson SE. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000; 9: 345-349 [PMID: 10794477]
156. Ma J, Pollak M, Giovannucci E, Chan JM, Tao Y, Hennekens C, Stampfer MJ. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm IGF Res 2000; 10 Suppl A: S28-S29 [PMID: 10984282 DOI: 10.1016/S1096-6374(00)90013-3]
157. Kukliński A, Kamocki Z, Cepowicz D, Gryko M, Czyzewska J, Pawlak K, Ke¸dra B. Relationships between insulin-like growth factor i and selected clinico-morphological parameters in colorectal cancer patients. Pol Przegl Chir 2011; 83: 250-257 [PMID: 22166477 DOI: 10.2478/v10035-011-0039-z]
158. Matuschek C, Rudoy M, Peiper M, Gerber PA, Hoff NP, Buhren BA, Flehmig B, Budach W, Knoefel WT, Bojar H, Prisack HB, Steinbach G, Shukla V, Schwarz A, Kammers K, Erhardt A, Scherer A, Bölke E, Schauer M. Do insulin-like growth factor associated proteins qualify as a tumor marker? Results of a prospective study in 163 cancer patients. Eur J Med Res 2011; 16: 451-456 [PMID: 22024424 DOI: 10.1186/2047-783X-16-10-451]
159. Soubry A, Il'yasova D, Sedjo R, Wang F, Byers T, Rosen C, Yashin A, Ukraintseva S, Haffner S, D'Agostino R. Increase in circulating levels of IGF-1 and IGF-1/IGFBP-3 molar ratio over a decade is associated with colorectal adenomatous polyps. Int J Cancer 2012; 131: 512-517 [PMID: 21898383 DOI: 10.1002/ijc.26393]
160. Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, Boeing H, Pischon T, Panico S, Agnoli C, Palli D, Tumino R, Vineis P, Peeters PH, van Gils CH, Bueno-de- Mesquita BH, Vrieling A, Allen NE, Roddam A, Bingham S, Khaw KT, Manjer J, Borgquist S, Dumeaux V, Torhild Gram I, Lund E, Trichopoulou A, Makrygiannis G, Benetou V, Molina E, Donate Suárez I, Barricarte Gurrea A, Gonzalez CA, Tormo MJ, Altzibar JM, Olsen A, Tjonneland A, Grønbaek H, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Slimani N, Boffetta P, Jenab M, Riboli E, Kaaks R. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. Int J Cancer 2010; 126: 1702-1715 [PMID: 19810099]
161. Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73-82 [PMID: 8402902 DOI: 10.1016/0092-8674(93)90680-O]
162. Wang Y, Hua S, Tian W, Zhang L, Zhao J, Zhang H, Zhang W, Xue F. Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent. Gynecol Oncol 2012; 125: 734-741 [PMID: 22426488 DOI: 10.1016/j.ygyno.2012.03.012]
163. Kuklinski A, Kamocki Z, Koda M, Piotrowski Z, Sulkowski S, Lesniewicz R, Pawlak K, Mysliwiec P, Kedra B. IGF-IR in patients with advanced colorectal cancer in correlation with certain clinico-morphological factors: Initial report. Oncol Lett 2011; 2: 1155-1159 [PMID: 22848281]
164. Zhao R, Berho M, Nogueras J, Sands D, Weiss E, Wexner S, Giardiello FM, Cruz-Correa M. Positive correlation of insulin-like growth factor-II with proliferating cell index in patients with colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2005; 14: 1819-1822 [PMID: 16030122 DOI: 10.1158/1055-9965.EPI-04-0803]
165. Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res 2008; 14: 8263-8269 [PMID: 19073970 DOI: 10.1158/1078-0432.CCR-08-0480]
166. Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC, Wang HP, Wu MS, Lin JT. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab 2010; 95: 1717-1725 [PMID: 20157191 DOI: 10.1210/jc.2009-2668]
167. LeRoith D, Roberts CT. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195: 127-137 [PMID: 12767520 DOI: 10.1016/S0304-3835(03)00159-9]
168. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012; 12: 159-169 [PMID: 22337149]
169. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21: 215-244 [PMID: 10857553 DOI: 10.1210/edrv.21.3.0399]
170. Ouyang H, Shiwaku HO, Hagiwara H, Miura K, Abe T, Kato Y, Ohtani H, Shiiba K, Souza RF, Meltzer SJ, Horii A. The insulin-like growth factor II receptor gene is mutated in genetically unstable cancers of the endometrium, stomach, and colorectum. Cancer Res 1997; 57: 1851-1854 [PMID: 9157973]
171. Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm KH, Kimmig R, Kasimir-Bauer S. Loss of heterozygosity proximal to the M6P/IGF2R locus is predictive for the presence of disseminated tumor cells in the bone marrow of ovarian cancer patients before and after chemotherapy. Genes Chromosomes Cancer 2011; 50: 598-605 [PMID: 21563231 DOI: 10.1002/gcc.20882]
172. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996; 28: 619-637 [PMID: 8673727 DOI: 10.1016/1357-2725(96)00005-2]
173. Williams AC, Collard TJ, Perks CM, Newcomb P, Moorghen M, Holly JM, Paraskeva C. Increased p53-dependent apoptosis by the insulin-like growth factor binding protein IGFBP-3 in human colonic adenoma-derived cells. Cancer Res 2000; 60: 22-27 [PMID: 10646845]
174. Kirman I, Poltoratskaia N, Sylla P, Whelan RL. Insulin-like growth factor-binding protein 3 inhibits growth of experimental colocarcinoma. Surgery 2004; 136: 205-209 [PMID: 15300181 DOI: 10.1016/j.surg.2004.04.020]
175. Durai R, Yang W, Gupta S, Seifalian AM, Winslet MC. The role of the insulin-like growth factor system in colorectal cancer: review of current knowledge. Int J Colorectal Dis 2005; 20: 203-220 [PMID: 15650828 DOI: 10.1007/s00384-004-0675-4]
176. Georges RB, Adwan H, Hamdi H, Hielscher T, Linnemann U, Berger MR. The insulin-like growth factor binding proteins 3 and 7 are associated with colorectal cancer and liver metastasis. Cancer Biol Ther 2011; 12: 69-79 [PMID: 21525788 DOI: 10.4161/cbt.12.1.15719]
177. Ruan W, Xu E, Xu F, Ma Y, Deng H, Huang Q, Lv B, Hu H, Lin J, Cui J, Di M, Dong J, Lai M. IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther 2007; 6: 354-359 [PMID: 17312390 DOI: 10.4161/cbt.6.3.3702]
178. Kaplan RC, Bùzková P, Cappola AR, Strickler HD, McGinn AP, Mercer LD, Arnold AM, Pollak MN, Newman AB. Decline in circulating insulin-like growth factors and mortality in older adults: cardiovascular health study all-stars study. J Clin Endocrinol Metab 2012; 97: 1970-1976 [PMID: 22442270 DOI: 10.1210/jc.2011-2967]
179. Rowlands MA, Holly JM, Hamdy F, Phillips J, Goodwin L, Marsden G, Gunnell D, Donovan J, Neal DE, Martin RM. Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes Control 2012; 23: 347-354 [PMID: 22183619 DOI: 10.1007/s10552-011-9883-8]
180. Wu K, Feskanich D, Fuchs CS, Chan AT, Willett WC, Hollis BW, Pollak MN, Giovannucci E. Interactions between plasma levels of 25-hydroxyvitamin D, insulin-like growth factor (IGF)-1 and C-peptide with risk of colorectal cancer. PLoS One 2011; 6: e28520 [PMID: 22216097 DOI: 10.1371/journal.pone.0028520]
181. Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 620-625 [PMID: 10203281 DOI: 10.1093/jnci/91.7.620]
182. Kaaks R, Toniolo P, Akhmedkhanov A, Lukanova A, Biessy C, Dechaud H, Rinaldi S, Zeleniuch-Jacquotte A, Shore RE, Riboli E. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592-1600 [PMID: 11018095 DOI: 10.1093/jnci/92.19.1592]
183. Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2005; 14: 850-855 [PMID: 15824155 DOI: 10.1158/1055-9965.EPI-04-0661]